$4.13
21.52% today
Nasdaq, Feb 28, 04:49 pm CET
ISIN
US4622601007
Symbol
IOVA
Sector
Industry

Iovance Biotherapeutics Inc Stock price

$5.26
-0.99 15.84% 1M
-6.14 53.86% 6M
-2.14 28.92% YTD
-12.21 69.89% 1Y
-10.41 66.43% 3Y
-27.77 84.08% 5Y
-3.72 41.43% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.09 1.68%
ISIN
US4622601007
Symbol
IOVA
Sector
Industry

Key metrics

Market capitalization $1.60b
Enterprise Value $1.28b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 14.14
P/S ratio (TTM) P/S ratio 17.64
P/B ratio (TTM) P/B ratio 2.07
Revenue growth (TTM) Revenue growth 12,751.20%
Revenue (TTM) Revenue $90.86m
EBIT (operating result TTM) EBIT $-429.96m
Free Cash Flow (TTM) Free Cash Flow $-374.08m
Cash position $397.49m
EPS (TTM) EPS $-1.50
P/E forward negative
P/S forward 10.04
EV/Sales forward 8.08
Short interest 23.06%
Show more

Is Iovance Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Iovance Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Iovance Biotherapeutics Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Iovance Biotherapeutics Inc forecast:

Buy
87%
Hold
13%

Financial data from Iovance Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
91 91
12,697% 12,697%
100%
- Direct Costs 109 109
268% 268%
120%
-18 -18
38% 38%
-20%
- Selling and Administrative Expenses 73 73
42% 42%
80%
- Research and Development Expense 298 298
12% 12%
328%
-388 -388
7% 7%
-427%
- Depreciation and Amortization 42 42
43% 43%
46%
EBIT (Operating Income) EBIT -430 -430
4% 4%
-473%
Net Profit -410 -410
5% 5%
-451%

In millions USD.

Don't miss a Thing! We will send you all news about Iovance Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Iovance Biotherapeutics Inc Stock News

Neutral
Seeking Alpha
about 14 hours ago
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q4 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO and President Dan Kirby - CCO Igor Bilinsky - COO Jean-Marc Bellemin - CFO Friedrich Graf Finckenstein - CMO Conference Call Participants Andrea Newkirk - Goldman Sachs Peter Lawson - Barcla...
Neutral
GlobeNewsWire
about 20 hours ago
Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M
Positive
The Motley Fool
8 days ago
If you're struggling to find compelling prospects for your portfolio right now, you're not alone. The market's usual favorites are seemingly out of favor.
More Iovance Biotherapeutics Inc News

Company Profile

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Head office United States
CEO Frederick Vogt
Employees 557
Founded 2007
Website www.iovance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today